Medtronic plc announced that the U.S. Food and Drug Administration granted clearance for its Stealth AXiS surgical system on February 13, 2026, allowing the company to begin commercial sales in the United States. The clearance marks a significant milestone for Medtronic’s spine portfolio, adding a next‑generation platform that combines pre‑operative planning, intra‑operative navigation, and robotic assistance.
The Stealth AXiS platform incorporates Medtronic’s LiveAlign segmental tracking, an industry‑first feature that provides real‑time visualization of spinal motion and surgical adjustments without repeated imaging. The system is designed to accommodate a wide range of surgeon preferences and care settings—from large hospitals to ambulatory surgery centers—promising to improve procedural efficiency and patient outcomes while reducing radiation exposure.
Medtronic’s recent financial results underscore the strategic importance of the new product. In the third quarter of fiscal 2025, the company reported worldwide revenue of $8.292 billion, up 2.5% year‑over‑year, and in the fourth quarter of fiscal 2025 revenue rose to $8.900 billion. The first quarter of fiscal 2026 saw revenue of $8.600 billion, and the second quarter of fiscal 2026 reached $8.960 billion. Building on this momentum, Medtronic raised its fiscal 2026 organic revenue growth guidance to approximately 5.5% and its non‑GAAP EPS guidance to $5.62‑$5.66, reflecting confidence in continued demand across its core segments.
Senior Vice President and President of Medtronic Cranial & Spinal Technologies, Michael Carter, said the Stealth AXiS system “addresses variability challenges in spine surgery by making advanced technology more usable.” Dr. Ronald Lehman Jr., a paid consultant to Medtronic, described the system’s real‑time visibility as “game‑changing technology.” CEO Geoff Martha highlighted the company’s broader AiBLE smart ecosystem strategy, noting that the new platform strengthens Medtronic’s position in the growing spine surgery market and supports its goal of accelerating revenue growth through integrated solutions.
The clearance positions Medtronic to compete with other advanced surgical navigation and robotic platforms in the spine market. By offering a unified system that blends planning, navigation, and robotics, Medtronic can capture a larger share of the market, which is projected to expand as demand for minimally invasive spine procedures rises. The Stealth AXiS platform also lays the groundwork for future cranial and ENT applications, potentially broadening Medtronic’s product reach within the AiBLE ecosystem.
Overall, the FDA approval of the Stealth AXiS system strengthens Medtronic’s spine segment, aligns with its strategy to deliver integrated surgical solutions, and supports the company’s upward revenue and earnings guidance for fiscal 2026. The new platform is expected to drive incremental revenue, enhance procedural outcomes, and reinforce Medtronic’s leadership in the evolving spine surgery market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.